Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT02981719 | Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer | completed | N/A | 61 | Fuda Cancer Hospital, GuangzhouOTHER |
| 1 |
| Jan 22, 2021 |
| clinicaltrials |
| NCT01104129 | Stool Testing for Pancreatic Cancer | completed | — | 158 | Columbia UniversityOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT03770117 | Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease(SIPUP) | completed | — | 113 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | Jan 19, 2021 | clinicaltrials |
| NCT03622229 | EUS-FNB for Solid Pancreatic Lesions: Side-fenestrated Vs Fork-tip Needle | completed | N/A | 192 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT02790333 | Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic Fistula | completed | N/A | 94 | Yi-Ping MouOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT02511821 | Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery | completed | N/A | 22 | City of Hope Medical CenterOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT01652976 | Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma(FOLFOX-D) | completed | Phase 2 | 44 | University of FloridaOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT02442323 | A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients | completed | N/A | 50 | Fox Chase Cancer CenterOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03466593 | Effects of Prehabilitation and Early Mobilization for Patients Undergoing Pancreas Surgery.(PreMob) | completed | N/A | 245 | Göteborg UniversityOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03207724 | Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia(OnFX) | completed | Phase 1 | 16 | Andrew Hendifar, MDOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT04196816 | Surgery for Pancreatic Cancer With Oligo-Metastasis(SPaM) | completed | — | 200 | University Hospital, MontpellierOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT00560963 | Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine | completed | Phase 1 / Phase 2 | 21 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01487785 | Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT02332863 | Comparison of Back-loaded vs Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement in Pancreatic Cancer. | completed | N/A | 44 | University of Colorado, DenverOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT03766295 | Masitinib Plus Gemcitabine in Pancreatic Cancer | completed | Phase 3 | 377 | AB ScienceINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT04064034 | ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer | completed | N/A | 60 | Mayo ClinicOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT04053998 | Benchmarking Outcomes in Pancreatic Surgery - WhippleBenchmarks.Org | completed | — | 1,462 | Royal Free Hospital NHS Foundation TrustOTHER | 2 | Nov 20, 2020 | clinicaltrials |
| NCT03790423 | 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer | completed | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT01397019 | Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours | completed | Phase 2 | 56 | Per PfeifferOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03180437 | Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 62 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT00026104 | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00114179 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02459652 | Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 57 | Japan Adjuvant Study Group of Pancreatic CancerOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT02340728 | Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies | completed | Phase 3 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02555813 | Treatment of Pancreatic Cancer With Abraxane | completed | — | 317 | CelgeneINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02704143 | Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer | completed | N/A | 63 | Changhai HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02923921 | Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer(Sequoia) | completed | Phase 3 | 567 | Eli Lilly and CompanyINDUSTRY | 13 | Oct 19, 2020 | clinicaltrials |
| NCT02045602 | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Theriva Biologics SLINDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02101580 | Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer | completed | Phase 1 | 21 | Polaris GroupINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT03322592 | EUS-FNB With ROSE Vs. EUS-FNB Without ROSE(FROSENOR) | completed | N/A | 800 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 8 | Sep 30, 2020 | clinicaltrials |
| NCT03962478 | Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction(HIFU) | completed | N/A | 92 | Xuzhou Central HospitalOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT01385956 | SOM 230 and Gemcitabine in Advanced Pancreatic Cancer | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT02289898 | Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma(YOSEMITE) | completed | Phase 2 | 207 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 6 | Sep 28, 2020 | clinicaltrials |
| NCT02355535 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | completed | Phase 1 | 48 | Vanquish Oncology, Inc.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT04560270 | CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer | completed | N/A | 69 | Poitiers University HospitalOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT03794128 | A Study of Personalized Neoantigen Cancer Vaccines | completed | — | 93 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT01189929 | A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 57 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT02005315 | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 1 | 30 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02050178 | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 1 | 26 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT02172976 | Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma | completed | Phase 2 / Phase 3 | 40 | Krankenhaus NordwestOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00267020 | Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 130 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT01441492 | Pancreas Resection With and Without Drains | completed | N/A | 399 | Baylor College of MedicineOTHER | 2 | Aug 31, 2020 | clinicaltrials |
| NCT00094445 | Trial of Curcumin in Advanced Pancreatic Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2020 | clinicaltrials |
| NCT02790944 | Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer | completed | — | 300 | Ambry GeneticsINDUSTRY | 1 | Aug 25, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jan 26, 2021source: clinicaltrials